Breaking Finance News

A statement released earlier today by HC Wainwright about Juniper Pharmaceuticals Inc (NASDAQ:JNP) bumps the target price to $6.75

Having a price of $5.91, Juniper Pharmaceuticals Inc (NASDAQ:JNP) traded 0.71% higher on the day. The last stock price close is down 19.02% from the two hundred day average, compared to the S&P 500 which has fallen -0.01% over the same period. JNP has recorded a 50-day moving average of $6.48 and 200-day moving average of $6.99. Trade volume was was down over the average, with 15,805 shares of JNP changing hands under the typical 27,998 shares.

Juniper Pharmaceuticals Inc (NASDAQ:JNP) had its target price upped to $7 by HC Wainwright in an issued report released 8/19/2016. The new target price indicates a possible upside of 0.14% based on the company’s last stock close price.

On 8/19/2016, H.C. Wainwright reported about Juniper Pharmaceuticals Inc(NASDAQ:JNP) bumped the target price from $0.00 to $6.75. At the time, this indicated a possible upside of 0.17%.

See Chart Below:

Juniper Pharmaceuticals Inc (NASDAQ:JNP)

A total of 3 firms have released a research note on the company. Zero rate the company a strong buy, two firms rate the stock a buy, 0 firms rate the company a hold, 0 rate the company to underperform, and lastly 0 brokeragesrate the company as sell with a one year target of $16.33

With a market capitalization of $0.0, Juniper Pharmaceuticals Inc has a PE of 0 with a 52 week low of $4.30 and a one-year high of $14.59.

About Juniper Pharmaceuticals Inc (NASDAQ:JNP)

Juniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE. The product segment also includes the royalty stream the Company receives from Allergan for CRINONE sales in the United States, as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services for the its customers, as well as characterizing and developing pharmaceutical product candidates for its internal programs, and managing the preclinical and clinical manufacturing of COL-1077 and its intra-vaginal ring (IVR). Its product and product development programs include CRINONE 8%, COL-1077, JNP-0101, and JNP-0101 and JNP-0301.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *